EN DE
Watch Botanix Pharmaceuticals Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Botanix Pharmaceuticals Ltd (BOT) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Botanix Pharmaceuticals Ltd stock A$0.01, price A$0.01, that is 23.0% below the price, quality 30 out of 100. Rating: overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare AU · ISIN AU000000BOT2

BP Botanix Pharmaceuticals Ltd logo Thin data Nov 4, 2026

Botanix Pharmaceuticals Ltd

BOT · AU
Expensive, weak quality

Our calculation puts a fair price 23% below what the stock costs today.

Low debt
Mixed Growth (revenue 5y +38.0 %/yr in AUD)
Mixed vs. peers (4/8)
Fair value A$0.0077 · Overvalued
Quality 30/100
Negative free cash flow
Narrow moat 9/100 · thin data
Thin data
⚠ Dilution
Watch Botanix Pharmaceuticals Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

A$0.5200 A$0.0090 Fair Value A$0.0077 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

60‑month range A$0.0090 – A$0.5200 · fair‑value band A$0.0077 – A$0.0085 · the A$0.0100 price screens above the A$0.0077 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 4, 2026.

Follow Botanix Pharmaceuticals in your weekly email

Every Wednesday you see whether Botanix Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States.

Show moreShow less

The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older.

Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers; BTX 1801 for treating staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 for the treatment of papulopustular rosacea; and BTX 1204A for treating atopic dermatitis.

The company was incorporated in 1984 and is based in Melbourne, Australia.

Stock analysis

Botanix Pharmaceuticals Ltd (BOT) currently trades at A$0.0100, while our model-based Fair Value estimate is A$0.0077, 23% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: A$0.0077 (bear) to A$0.0085 (bull), the price of A$0.0100 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Botanix Pharmaceuticals Ltd reported revenue of A$34.5M in FY2026 versus A$2.8M in FY2022, a compound +88.1%/yr. Reported net income was −A$69.8M in FY2026.

Key figures

Market cap A$33.1M (≈ $22.8M) Micro · P/S ratio 0.98 · EPS (TTM) A$−0.0400 · Return on equity −96.4% · Return on assets (EBIT) −61.4% (5-year average) · Operating margin −206% · Revenue (TTM) A$33.8M · Revenue growth (YoY) +220%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (low confidence).

What moves the price

The share trades about 93% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −23%, BOT screens richer than that median.

Fair Value models

Bear A$0.0077 Fair Value A$0.0077 Bull A$0.0085
Price A$0.0100 · Downside -23.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) A$0.0100 A$0.0100 A$0.0200 52
All 1 models by family
Asset-Based
NCAV (Graham) A$0.0100 A$0.0100 A$0.0200 52

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 30/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 3
How much profit the company makes from its sales and capital
Quality Growth 72
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 69
Debt, balance sheet and risk of trouble
Investment 33
Does it invest with discipline instead of growing at any price?
Low Volatility 36
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+496.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+235.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+38.0%
Start year 2021 (pandemic)
Revenue growth 37 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−149.1% (2021) → −200.8% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

BOT screens overvalued: fair value 23% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Botanix Pharmaceuticals Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 4/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 30 · Bottom 25%
Fair Value upside −23.0% · Above median
Profitability
Return on assets −65.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 219.6% · Top 25%
Balance sheet
Debt / equity 0.17× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.52× · Cheapest 25%
P/S (12 months) 0.98× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)3 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)91 · sector 97
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs BOT
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs BOT
Genmab A/S GMAB kr 3,527 kr 3,999 +13% vs BOT
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs BOT
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs BOT
Vertex Pharmaceuticals Incorporated VRTX $547.09 $596.75 +9% vs BOT
argenx SE ARGX $927.21 $908.40 −2% vs BOT
CSL Limited CSL A$200.77 A$183.04 −9% vs BOT
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs BOT
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs BOT

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Botanix Pharmaceuticals Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Botanix Pharmaceuticals Ltd Fair Value". https://www.fairvalue-calculator.com/stock/BOT

Frequently asked questions

Is Botanix Pharmaceuticals Ltd (BOT) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of A$0.0077 versus a price of A$0.0100, about 23% lower (overvalued).
What is the fair value of BOT?
Our model-based fair value for Botanix Pharmaceuticals Ltd is A$0.0077 (as of Nov 4, 2026), built from audited fundamentals. The current price: A$0.0100.
What is the quality score of BOT?
Botanix Pharmaceuticals Ltd has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Botanix Pharmaceuticals Ltd (BOT)?
Our model-based price target is the fair value of A$0.0077 (as of Nov 4, 2026) from 1 valuation models. Cautious scenario A$0.0077, optimistic scenario A$0.0085. It is a calculation from audited fundamentals, not an analyst target.
What is the Botanix Pharmaceuticals Ltd stock forecast for 2026?
Our models put fair value at A$0.0077, about 23% lower versus a price of A$0.0100 (overvalued). Cautious scenario A$0.0077, optimistic scenario A$0.0085. The calculation is refreshed regularly with new filings.
What is the revenue of Botanix Pharmaceuticals Ltd (BOT)?
Botanix Pharmaceuticals Ltd reported trailing-twelve-month revenue of about A$33.8M (latest available figure, as of Nov 4, 2026).
What is the intrinsic value of Botanix Pharmaceuticals Ltd (BOT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Botanix Pharmaceuticals Ltd it is A$0.0077 per share (as of Nov 4, 2026), against a price of A$0.0100. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Botanix Pharmaceuticals Ltd stock overvalued or undervalued in 2026?
As of Nov 4, 2026, BOT trades above its calculated fair value: price A$0.0100, fair value A$0.0077, a gap of about −23% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BOT?
No. The price is what the market pays today (A$0.0100); the fair value is what the company's own numbers justify (A$0.0077). For Botanix Pharmaceuticals Ltd the two are A$0.0023 per share apart. That gap is exactly why we show both numbers side by side.
How much is Botanix Pharmaceuticals Ltd worth?
The market values Botanix Pharmaceuticals Ltd at about A$33.1M (market capitalisation, as of Nov 4, 2026). Per share that is A$0.0100; our models calculate a fair value of A$0.0077 per share.
What do the bullish and bearish scenarios say about BOT?
Our models span a range for Botanix Pharmaceuticals Ltd: cautious scenario A$0.0077, base A$0.0077, optimistic A$0.0085 per share (as of Nov 4, 2026, price A$0.0100). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Botanix Pharmaceuticals Ltd (BOT)?
Balance-sheet figures for Botanix Pharmaceuticals Ltd (as of Nov 4, 2026): return on equity −96.4%, debt of 0.17 per unit of equity. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is BOT from its 52-week high?
Botanix Pharmaceuticals Ltd trades at A$0.0100, about 93% below its 52-week high of A$0.1400 and 11% above the low of A$0.0090 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0077 is for.
Which stocks are comparable to Botanix Pharmaceuticals Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Botanix Pharmaceuticals Ltd stock attractive at the current price?
The data as of Nov 4, 2026: price A$0.0100, calculated fair value A$0.0077 (−23%), Quality Score 30/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BOT calculated?
We run Botanix Pharmaceuticals Ltd through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of A$0.0077 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Botanix Pharmaceuticals Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Botanix Pharmaceuticals Ltd (BOT)?
The closing price on Nov 9, 2026 was A$0.0100. Our model-based fair value is A$0.0077, about 23% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Botanix Pharmaceuticals Ltd right now?
The price sits above even our optimistic bull case (A$0.0085). The favourable scenario is already priced in. Weak quality (30/100) and above fair value at the same time, the margin of safety is missing on both counts. The models converge in a tight band (A$0.0077 to A$0.0085), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Botanix Pharmaceuticals Ltd

How large is the market capitalisation of Botanix Pharmaceuticals Ltd (BOT)?
The market capitalisation of Botanix Pharmaceuticals Ltd is A$33.1M (≈ $22.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Botanix Pharmaceuticals Ltd (BOT)?
The price-to-sales ratio of Botanix Pharmaceuticals Ltd is 0.98 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Botanix Pharmaceuticals Ltd (BOT)?
Earnings per share at Botanix Pharmaceuticals Ltd are A$−0.0400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Botanix Pharmaceuticals Ltd (BOT)?
The return on equity (ROE) of Botanix Pharmaceuticals Ltd is −96.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Botanix Pharmaceuticals Ltd (BOT)?
On an EBIT basis the return on assets of Botanix Pharmaceuticals Ltd is −61.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Botanix Pharmaceuticals Ltd (BOT)?
The operating margin of Botanix Pharmaceuticals Ltd is −206% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Botanix Pharmaceuticals Ltd (BOT)?
Revenue at Botanix Pharmaceuticals Ltd is growing +220% versus a year earlier (3y avg +235%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Botanix Pharmaceuticals Ltd (BOT) generate?
The free cash flow of Botanix Pharmaceuticals Ltd is −A$64.6M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Botanix Pharmaceuticals Ltd (BOT) hold?
Botanix Pharmaceuticals Ltd holds more cash than debt, A$21.9M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Botanix Pharmaceuticals Ltd in the live analysis

One click puts Botanix Pharmaceuticals Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.